The market for cancer vaccines is much smaller than other cancer therapeutic categories. The size of the market can be attributed to the nascent stages of industry life cycle and the late introduction of the vaccines in the market. To tap this market, many companies from North America are actively investing in cancer vaccine development. The market penetration is expected to increase with the increase in competition among the various pharmaceutical companies to obtain a larger portion of this market.
The North America Cancer Vaccines Market is segmented based on:
Live Attenuated Vaccines
Recombinant Vector Vaccines
Dendritic Cell Vaccines
According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers.
North America dominates the market, with U.S. accounting for a major market share. However, it is poised to grow at the second highest CAGR during the forecast period owing to governmental initiatives, rising focus of major players on the Indian vaccine technology market, and increasing immunization initiatives by organizations such as World Health Organization and GAVI in these regions.
Some of the key participants in the industry include Prima BioMed, GlaxoSmithKline, Sanofi S.A, Merck, Aduro BioTech, AstraZeneca plc, OXFORD BIOMEDICA etc.
Increasing cancer cases
Drug innovations with regard to the cancer
Rise in aging populace
Advanced health care services
Upsurge in awareness about cancer and their available therapies in the market
Increasing health care expenditure
Cold chain, or temperature-controlled supply chain, management
Low accessibility to vaccines in remote areas
Stringent regulatory procedures
SPECIALITIES OF THIS REPORT
The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
The report contains wide range of information about the leading market players and the major strategies adopted by them.
WHAT THE REPORT OFFERS
Market definition along with identification of key drivers and restraints for the market.
Market analysis with region specific assessments and competition analysis on a global andregional scale.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
2. Research Methodology
3.1 Report Description
3.2 Markets Covered
4. Market Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Increased Prevalence of Cancers
4.2.2 Rising Government and Non-Government Funding for Vaccine Development
4.2.3 Increasing Investments By Companies
4.2.4 Technological Advancements
4.3 Market Restraints
4.3.1 Cold Chain Management
4.3.2 Huge Capital Investments
4.3.3 Stringent Regulatory Procedures
4.4 Market Opportunitites
4.5 Market Threats
5. Porters Five Force Analysis
5.1 Bargaining Power of suppliers
5.2 Bargaining power of buyers
5.3 Degree of competition
5.4 Threat of substitution
5.5 Threat of new entrants
6. Market Segmentation
6.1 By Technology
6.1.1 Subunit Vaccines
6.1.2 Live Attenuated Vaccines
6.1.3 Conjugate Vaccines
6.1.4 Inactivated Vaccines
6.1.5 Recombinant Vector Vaccines
6.1.6 Toxoid Vaccines
6.1.7 Synthetic Vaccines
6.1.8 Dendritic Cell Vaccines
6.2 By Type
6.2.1 Preventive Vaccines
6.2.2 Therapeutic Vaccines
6.3 By Disease Indication
6.3.1 Cervical cancer
6.4 By End User
6.5 By Geography
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Collaborations & Partnerships
7.3 New Product Launches
7.4 Recommendations to new market players
7.5 Value Chain Analysis
8. Company Profiles
8.1 AstraZeneca plc
8.2 Aduro BioTech
8.4 Galena Biopharma
8.5 Juvaris Biotherapeutics
8.7 Oxford BioMedica
8.8 Prima BioMed